ClinicalTrials.gg
Not yet recruitingNCT07874282Updated Nov 6, 2026

Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer

A Phase 2 interventional study of Telisotuzumab adizutecan plus RC148(ABBV-1480) and Telisotuzumab adizutecan plus RC148(ABBV-1480) in Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology, sponsored by RemeGen Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Nov 6, 2026Interventions changedTitle changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To Evaluate the Safety, Tolerability, and Preliminary Antitumor Efficacy of RC148 in Combination with Telisotuzumab adizutecan as First-line Treatment for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

02

Conditions studied

  • Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology
03

In context

Lead sponsor

RemeGen Co., Ltd. is the lead sponsor of 83 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily agrees to participate in the study and provides signed
  2. Willing and able to comply with study and follow-up procedures
  3. Male or female, aged 18-80 years
  4. Expected survival≥3 months
  5. (ECOG) performance status of 0 or 1
  6. Histopathologically or confirmed locally advanced or non-squamous NSCLC not amenable to curative-intent therapy
  7. No prior systemic anti-neoplastic therapy for advanced or metastatic non-squamous NSCLC
  8. At least one measurable non-cerebral lesion per v1.1
  9. Availability of c-Met expression, expression and driver gene test results including at minimum EGFR and ALK for enrollment
  10. Adequate cardiac, bone-marrow, hepatic, renal and coagulation function meeting relevant criteria
  11. Female study participants must be , surgically sterilized, or, if of , have a negative serum pregnancy test within 7 days prior to the first dose, agree to use at least one medically-accepted method during study treatment and for 12 months after the end of study treatment, and refrain from oocyte donation and breastfeeding during this period; male study participants must agree to use at least one medically-accepted contraceptive method during study treatment and for 12 months after the end of study treatment and refrain from sperm donation during this period

Exclusion criteria

Exclusion Criteria:

  1. confirmed presence of any squamous NSCLC, small-cell carcinoma, neuroendocrine carcinoma, or sarcoma component
  2. Known positive driver gene or gene mutations with approved treatment options
  3. Presence of active
  4. Screening-period imaging shows obvious tumor necrosis or cavitation, with bleeding risk upon study entry as judged by the investigator
  5. Received thoracic radiotherapy >30 Gy within 6 months prior to randomization; palliative local therapy for non-target lesions within 2 weeks prior to randomization; non-specific immunomodulatory therapy within 2 weeks prior to the first dose of study drug; or traditional Chinese herbal/proprietary medicine with anti-neoplastic indications within 1 week prior to randomization
  6. Prior immunotherapy, including , immune checkpoint agonists, immune-cell therapy, or any other therapies targeting tumor immune mechanisms
  7. Prior systemic anti-neoplastic therapies other than chemotherapy and PD-1/PD-L1 antibodies
  8. Systemic treatment with or other medications within 2 weeks prior to randomization
  9. Administration of any live or within 4 weeks prior to randomization, or planned administration of any live or live-attenuated vaccine during the study
  10. Participation in another clinical trial within 4 weeks prior to randomization
  11. Major surgery, interventional therapy, or severe trauma within 4 weeks prior to randomization, or planned major surgery during the study period; core-needle or other minor surgery within 7 days prior to the first dose
  12. History of severe coagulation disorders; or subjects receiving anticoagulant therapy, excluding prophylactic-dose anticoagulants such as low-molecular-weight heparin
  13. Toxicities from prior anti-neoplastic therapy not recovered to Grade 0-1 as defined by v6.0; except for alopecia, pigmentation, expected irrecoverable endocrinopathies from prior immunotherapy that are stably controlled with medication, and other conditions assessed by the investigator not interfering with study drug treatment
  14. For subjects previously exposed to PD-1/PD-L1 inhibitors: prior occurrence of immune-related adverse events (irAEs) Grade 3 or higher due to immunotherapy, irAEs leading to permanent treatment discontinuation, Grade 2 immune-related cardiac toxicity, or any-grade neurological or ocular irAEs; prior adverse events requiring immunosuppressive agents other than corticosteroids, or recurrent adverse events during prior immunotherapy requiring re-initiation of systemic corticosteroid therapy
  15. Presence of severe acute or chronic infection
  16. Hemoptysis, active gastrointestinal bleeding, peptic ulcer, epistaxis, or other bleeding events requiring intervention within 4 weeks prior to randomization; or severe esophagogastric varices, vasculitis, vascular ulcer, aneurysm, or vascular dissection judged by the investigator to carry a high bleeding risk
  17. Severe arterial/venous thromboembolic events or cerebrovascular accident within 6 months prior to the first dose
  18. Active or cardiac disease
  19. History of interstitial lung disease or pulmonary inflammation requiring systemic steroid therapy; or chest-CT at screening showing any evidence of active ILD/pulmonary inflammation, idiopathic pulmonary fibrosis, organizing pneumonia, treatment-induced pneumonitis, idiopathic pneumonia, radiation pneumonitis, severe impaired pulmonary function, or acute exacerbation of within 1 month prior to randomization
  20. History of gastrointestinal perforation and/or fistula, or gastrointestinal obstruction within 6 months prior to randomization
  21. Presence of systemic diseases that are not stably controlled as judged by the investigator
  22. Active disease, or prior history of autoimmune disease with potential for recurrence
  23. Subjects with a history of other acquired or congenital immunodeficiency diseases, or history of organ transplantation
  24. Known or delayed-type allergic reaction to any components of the study drug or analogous medicinal products
  25. Clinically symptomatic third-space effusion or third-space effusion requiring intervention
  26. Other diagnosed within 3 years prior to initiation of study drug administration
  27. Poor compliance; subjects expected to be unable to cooperate with completion of trial procedures
  28. Any other past or present disease, abnormal physical finding, or laboratory abnormality, in the investigator's opinion, rendering the subject unsuitable for study drug administration, likely to confound interpretation of study results, or placing the subject at high-risk
  29. Local or systemic disease not caused by malignancy, or diseases/symptoms secondary to the tumor, that may result in substantial medical risk and/or uncertainty in survival-time assessment, such as manifestations of cachexia
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Dose1:Telisotuzumab adizutecan plus RC148(ABBV-1480)

    Drug: Telisotuzumab adizutecan plus RC148(ABBV-1480)

  • Experimental
    Dose2:Telisotuzumab adizutecan plus RC148(ABBV-1480)

    Drug: Telisotuzumab adizutecan plus RC148(ABBV-1480)

Interventions

  • DrugTelisotuzumab adizutecan plus RC148(ABBV-1480)

    Dose1

  • DrugTelisotuzumab adizutecan plus RC148(ABBV-1480)

    Dose2

06

What researchers measure

Primary outcomes

  1. Objective Response Rate assessed by the investigators according to RECIST v1.1

    Time frame: 24 months

07

Study locations

1 site
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 14, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2027
CompletionEst.
Feb 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Drug: Telisotuzumab adizutecan plus RC148(ABBV-1480); removed Drug: Telisotuzumab adizutecan plus RC148. Arm changed Dose1:Telisotuzumab adizutecan plus RC148→Dose1:Telisotuzumab adizutecan plus RC148(ABBV-1480); Dose2:Telisotuzumab adizutecan plus RC148→Dose2:Telisotuzumab adizutecan plus RC148(ABBV-1480)
Nov 6, 2026
Title
Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
Nov 6, 2026
Registered
First appeared on the registry
Oct 14, 2026
Show all 2 updates
  1. Nov 6, 2026
    Interventions Added Drug: Telisotuzumab adizutecan plus RC148(ABBV-1480); removed Drug: Telisotuzumab adizutecan plus RC148. Arm changed Dose1:Telisotuzumab adizutecan plus RC148→Dose1:Telisotuzumab adizutecan plus RC148(ABBV-1480); Dose2:Telisotuzumab adizutecan plus RC148→Dose2:Telisotuzumab adizutecan plus RC148(ABBV-1480)
    Title Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
    + 1 other change: verification date
  2. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07874282
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Oct 14, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Feb 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Jiang Guo
Contact
jiang.guo@remegen.com
010-65384976

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion